Immunocore's (IMCR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a research note released on Wednesday morning,Benzinga reports. They currently have a $100.00 price target on the stock.

A number of other analysts also recently issued reports on IMCR. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research report on Thursday, February 27th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $65.64.

Immunocore Stock Up 1.9 %

Shares of Immunocore stock traded up $0.53 during trading on Wednesday, reaching $28.80. The stock had a trading volume of 345,561 shares, compared to its average volume of 431,489. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -30.32 and a beta of 0.79. The stock has a fifty day moving average price of $30.08 and a two-hundred day moving average price of $31.38. Immunocore has a 52 week low of $27.19 and a 52 week high of $66.00. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Remove Ads

Hedge Funds Weigh In On Immunocore

Institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Immunocore in the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. grew its position in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC grew its position in shares of Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Tema Etfs LLC acquired a new position in shares of Immunocore in the fourth quarter valued at approximately $330,000. Finally, Virtus ETF Advisers LLC grew its position in shares of Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.